Profile data is unavailable for this security.
About the company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated1994
- Employees84.59k
- LocationSanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
More ▼
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Ocular Therapeutix Inc | -0.46% | -- |
| Dynavax Technologies Corp | -0.06% | 1.93bn |
| Blueprint Medicines Corp | -6.11% | 9.10bn |
| Vigil Neuroscience Inc | -12.14% | 466.72m |
Data delayed at least 15 minutes, as of Feb 10 2026 14:38 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 6.85bn | 1.33bn | 51.80bn | 9.38k | 38.81 | 5.23 | 27.09 | 7.56 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| CSL Ltd | 13.20bn | 2.55bn | 52.09bn | 32.07k | 20.49 | 3.17 | 14.78 | 3.95 | 8.80 | 8.80 | 45.61 | 56.92 | 0.4019 | 1.20 | 5.16 | 691,665.10 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Merck KGaA | 21.27bn | 2.96bn | 53.17bn | 62.35k | 18.15 | 1.85 | 10.92 | 2.50 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 12.04bn | 3.82bn | 69.24bn | 15.41k | 18.59 | 2.64 | 16.20 | 5.75 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
| Chugai Pharmaceutical Co Ltd | 6.77bn | 2.34bn | 82.50bn | 7.78k | 34.60 | 7.41 | -- | 12.18 | 263.73 | 263.73 | 764.40 | 1,230.91 | 0.5379 | 1.41 | 3.59 | -- | 18.56 | 19.40 | 21.83 | 23.54 | 71.09 | 66.75 | 34.50 | 31.46 | 3.56 | 583.66 | -- | 40.95 | 7.46 | 9.84 | 12.06 | 15.11 | 12.69 | 17.27 |
| Sanofi SA | -100.00bn | -100.00bn | 97.91bn | 84.59k | -- | 1.36 | -- | -- | -- | -- | -- | 59.04 | -- | -- | -- | -- | -- | 4.87 | -- | 6.07 | -- | 70.15 | -- | 14.05 | -- | -- | 0.2209 | 77.13 | 5.49 | 4.57 | -10.13 | -16.67 | -- | 5.18 |
| Vertex Pharmaceuticals Inc | 9.84bn | 3.08bn | 100.27bn | 6.10k | 33.08 | 6.90 | 30.83 | 10.19 | 14.23 | 14.23 | 45.38 | 68.20 | 0.4978 | 1.19 | 6.34 | 1,921,853.00 | 15.60 | 14.06 | 19.02 | 16.67 | 86.28 | 87.35 | 31.35 | 26.28 | 2.00 | -- | 0.00 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| GSK plc | 37.54bn | 6.57bn | 101.14bn | 68.63k | 15.53 | 5.37 | 8.74 | 2.69 | 1.39 | 1.39 | 7.95 | 4.02 | 0.5418 | 1.54 | 4.57 | -- | 10.43 | 7.00 | 16.02 | 10.95 | 72.67 | 71.30 | 19.25 | 15.49 | 0.5416 | 16.90 | 0.5262 | 69.37 | 4.11 | 6.05 | 121.98 | 5.07 | 5.92 | -7.97 |
| Bristol-Myers Squibb Co | 40.45bn | 5.92bn | 103.83bn | 34.10k | 17.57 | -- | 11.33 | 2.57 | 3.46 | 3.46 | 23.63 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 72.62 | 76.32 | 14.64 | 8.34 | -- | 16.84 | -- | -- | -0.2195 | 2.54 | 178.83 | -- | -- | 0.658 |
| Pfizer Inc | 52.52bn | 6.50bn | 129.08bn | 81.00k | 19.96 | -- | 11.05 | 2.46 | 1.36 | 1.36 | 10.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 75.81 | 69.03 | 12.44 | 19.52 | -- | 9.38 | -- | -- | -1.65 | 8.48 | -3.42 | 3.16 | -- | 2.50 |
| Novo Nordisk A/S | 41.37bn | 13.71bn | 141.12bn | 68.79k | 13.50 | 7.12 | 8.50 | 3.41 | 23.03 | 23.03 | 69.49 | 43.66 | 0.6128 | 1.30 | 4.33 | 4,492,601.00 | 20.31 | 25.03 | 35.60 | 48.23 | 80.98 | 83.95 | 33.14 | 33.96 | 0.5696 | -- | 0.4029 | 50.28 | 6.43 | 19.48 | 1.43 | 19.44 | 32.48 | 20.79 |
Data as of Feb 10 2026. Currency figures normalised to Sanofi SA's reporting currency: Euro EUR
15.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 43.29m | 3.55% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 24.08m | 1.98% |
| Capital Research & Management Co. (World Investors)as of 08 Jan 2026 | 21.54m | 1.77% |
| Amundi Asset Management SASU (Investment Management)as of 30 Jan 2026 | 18.83m | 1.54% |
| Geode Capital Management LLCas of 05 Feb 2026 | 17.22m | 1.41% |
| BlackRock Advisors (UK) Ltd.as of 09 Jan 2026 | 16.31m | 1.34% |
| Dodge & Coxas of 31 Dec 2025 | 16.09m | 1.32% |
| GQG Partners LLCas of 31 Oct 2025 | 11.33m | 0.93% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 9.63m | 0.79% |
| Putnam Investment Management LLCas of 05 Feb 2026 | 9.28m | 0.76% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
